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Abstract. Background/Aim: A limitation to successful
cancer chemotherapy treatments is the acquisition of drug
resistance. In advanced-stage ovarian cancer, the
mammalian target of rapamycin (mTOR) pathway is up-
regulated, and inhibition of this pathway increases
chemosensitivity in ovarian carcinoma cell lines. In this
study, the expression of DEPTOR, mTOR, RICTOR,
RAPTOR and S6 kinases were investigated in SKOV-3 and
PEO1 parental and the paclitaxel-resistant (TaxR) SKOV-
3TaxR and PEO1TaxR cell lines. Materials and Methods:
RT-PCR, immunofluorescent analysis and Western blotting
were carried out. Results: Quantitative RT-PCR revealed
significant up-regulation of DEPTOR in both paclitaxel-
resistant cell lines. SKOV-3TaxR exhibited down-regulation
of RICTOR, RAPTOR and mTOR, whereas PEO1-TaxR
showed down-regulation of RAPTOR and up-regulation of
RICTOR and mTOR. Semi-quantitative RT-PCR analysis
revealed marked changes in the expression of p70S6K splice
variants mRNA in PEO1TaxR. Moreover, the
phosphorylation status of p70S6K at Ser371 appears to be
cell-type specific. Conclusion: We hypothesize that mTOR
signalling may play a role in mediating paclitaxel resistance
in ovarian cancer. 
Ovarian carcinoma is the gynaecological malignancy
associated with the highest mortality in industrialised
countries, with a reported 5-year survival rate of <30% (1).
The prognosis for patients with ovarian cancer is determined
by conventional factors such as surgical stage and
histological grade and type. Nevertheless, to the best of our
knowledge, no single molecular profile has helped identify
the most aggressive tumours, nor aided in the guidance of
suitable therapeutic strategies for specific patients. Many
carcinomas activate growth factor receptor signalling
pathways that exhibit genetic alterations involving either the
receptor, or other factors that drive the proliferation (2).
Interestingly, several pathways converge on the highly
conserved serine/threonine kinase mammalian target of
rapamycin (mTOR), which plays a central role in controlling
cell growth (3).
Current treatments for newly diagnosed ovarian tumours
centre on the use of platinum containing drugs such as
cisplatin or carboplatin and often in combination therapy
with paclitaxel (Taxol™). The treatment options for recurrent
or advanced disease depend on whether tumours are resistant
or refractory to previously used platinum-based drugs (4).
Most patients with advanced disease will be treated with
paclitaxel, or in combination with other agents, such as
topotecan (5). One of the most important factors affecting
patient survival is the development of drug resistance (6).
Chemoresistance to agents such as paclitaxel can be acquired
through a variety of mechanisms including altered drug
metabolism, reduction in sensitivity to cell death stimuli (7),
and alterations in microtubule dynamics (8, 9). The
multidrug-resistant phenotype (MDR) mediated by ATP-
binding cassette (ABC) transporters has been shown to be an
important correlate in taxane resistance in cultured cell line
models. ABCB1 (P-glycoprotein) is the drug transporter
most frequently associated with paclitaxel- and docetaxel-
resistant cell lines. To date, the clinical relevance of this in a
number of tumour types, including breast and ovarian, has
not been adequately verified (10). 
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The PI3K-Akt-mTOR pathway is activated in advanced-
stage disease (2, 11) and inhibition of this pathway with
inhibitors to Akt or its downstream effector, mTOR,
increases chemosensitivity to paclitaxel in ovarian carcinoma
cell lines (12, 13). Cell signalling by mTOR plays a critical
role in protein synthesis and proliferation of both normal and
malignant cells (14, 15). mTOR and one of its substrates, S6
kinase, have been shown to be activated in ovarian cancer
cell lines (16, 17). Inhibition of the mTOR pathways has
antiproliferative effects. Rapamycin inhibits the growth of a
broad spectrum of malignancies including pancreatic cancer,
leukaemia and B-cell lymphoma, (18). Inhibitors of mTOR
are known to increase chemosensitivity in a variety of
tumours including ovarian cancer cell lines (12, 19, 20).
Previous studies indicate that rapamycin may act as a
substrate for the MDR transporter P-glycoprotein and
consequently limit its utility in some tumours (21).
Treatment of several ovarian cancer cell lines with the
rapamycin analogue RAD001 (an inhibitor of mTOR)
resulted in dose-dependent growth inhibition (22).
Furthermore, in a transgenic mouse model of ovarian cancer,
RAD001-treated mice exhibited a delay in cancer
progression (11). Recently, a novel regulator of mTOR
signalling has been described, named DEPTOR (DEPDC6).
This molecule interacts with mTOR via its PDZ domain. In
a series of elegant experiments, Peterson et al., showed that
DEPTOR interacts with both mTORC1 and mTORC2
complexes. Inhibition of mTORC1 and overexpression of
DEPTOR relieves mTORC1-mediated inhibition of PI3K.
This leads to activation of PI3K and surprisingly activation
of mTORC2-dependent outputs (23).
In this study, the expression and activity of mTOR
signalling components in the context of paclitaxel-resistant
ovarian cancer was investigated. SKOV-3 and PEO1 (parental)
paclitaxel -sensitive and -resistant (TaxR) were used as
representative models of taxane-refractory ovarian cancer.
Materials and Methods
Cell culture. All cell culture reagents were obtained from Invitrogen
(Paisley, UK) unless stated otherwise. PEO1 and SKOV-3
paclitaxel-sensitive and -resistant ovarian cancer cell lines,
respectively, were developed by Dr Helen Coley, University of
Surrey (10). For PEO1, RPMI-1640 10% foetal calf serum (FCS),
5% penicillin-streptomycin and 2 mM glutamine were used for cell
culture at 37˚C with 5% CO2. The SKOV-3 cell line was cultured
in minimum essential medium/Earl’s salts non-essential amino acid
medium supplemented with 10% FCS, L-glutamine and the
penicillin-streptomycin mixture at 37˚C with 5% CO2.
Chemosensitivity testing for the assessment of sensitivity to the
mTOR inhibitor rapamycin. Rapamycin was obtained from Sigma
Aldrich (Poole, UK) and made up in sterile water as a stock
solution. XR9576 (Tariquidar) was obtained from Xenova PLC
(Slough, UK) and made up as a stock solution in dimethyl sulfoxide
(DMSO) and stored as frozen aliquots. PEO1 cell lines were set up
in 96-well plates at a cell density of 3×104 per ml and allowed to
attach for 24 h. Rapamycin diluted in tissue culture medium was
then added in increasing concentration in quadruplicate. Cells were
then placed back in the incubator for 72 h. 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide ( MTT) solution (5 mg/ml in
phosphate buffered saline; PBS) was added to each well in 20 μl
and left for 3-4 h to allow formazan crystal formation. Wells were
aspirated and 200 μl of DMSO added to dissolve formazan crystals.
The resulting purple coloration was measured at 540 nm in a plate
reading spectrophotomer. Dose–response curves were constructed
and used to determine the IC50 dose (defined as the drug dose that
gives rise to 50% loss of cell viability compared with untreated
control wells). In limited experiments, we used the MDR modulator
XR9576 at 100 nM in combination with rapamycin in order to
ascertain any MDR reversal effects.
RNA isolation, cDNA synthesis and PCR. Total ribonucleic acid was
isolated using an RNA extraction kit (Sigma Aldrich), according to
the manufacturer’s instructions. RNA concentration was determined
by spectrophotometric analysis (NanoDrop; Thermo Scientific, UK)
and agarose gel electrophoresis. RNA (500 ng) was reverse-
transcribed into cDNA using 5 IU/μl RNase H reverse transcriptase
(Invitrogen). PCR amplification was performed using Taq
polymerase (Invitrogen) and oligonucleotide primers as previously
described (24). A total of 28 cycles for each gene were performed,
consisting of a denaturing step at 94˚C for 30 s, extension at 60˚C
for 1 min and elongation at 72˚C for 1 min.
Quantitative RT-PCR. Relative expression of the genes of interest
was assessed by quantitative PCR (Q-PCR) on an ABI Prism
7900HT Sequence detection system (Applied Biosystems) using
SYBR® Green-PCR reaction mixture (Sigma Aldrich) and the
primers as follows: DEPTOR (202 bp): forward: 5’-caccatgtg
tgtgatgagca-3’, reverse: 5’-tgaaggtgcgctcatacttg-3’; RICTOR (117
bp): forward: 5’-ggaagcctgttgatggtgat-3’, reverse: 5’-ggcagcctgtttta
tggtgt-3’; RAPTOR (170 bp): forward: 5’-actgatggagtccgaaatgc-3’
reverse: 5’-tcatccgatccttcatcctc-3’; 18S RNA (155 bp): forward: 5’-
aaacggctaccacatccaag-3’, reverse: 5’-cctccaatggatcctcgtta-3’.
As a negative control, distilled water was used in place of the
cDNA. RNAs were assayed from two to three independent
biological replicates. The RNA levels were expressed as relative RQ
values, using the parental cell line as calibrator. The Delta Delta Ct
method was employed for comparing relative expression results
between treatments in Q-PCR (25). 
Immunofluorescent analysis. SKOV-3 and PEO1 cells were fixed in
4% paraformaldehyde for 10 min prior to washes in PBS and
incubation with 10% bovine serum albumin (BSA) for 1 h. Cells
were incubated for 1 h with an mTOR antibody (Santa Cruz
Biotechnology, USA) at a 1:100 dilution in 1% BSA PBS. Cells
were washed with PBS prior to an incubation with anti-rabbit IgG-
fluorescein isothiocyanate (FITC)-conjugated antibody (Santa Cruz
Biotechnology, USA) for 1 h. Slides were washed with PBS and
mounted in Vectashield® Mounting Medium (Vector Labs)
containing the dye 4,6-diamido-2-phenylindole (DAPI) to
counterstain nuclei. Images were captured using a Plan Apo
Neofluor X63 NA 1.25 oil objective (Zeiss) on a Zeiss Axiovert
200M microscope and viewed using AxioVision software, at set
exposure times.
Protein extraction from cultured cells. SKOV-3 and PEO1 cells were
cultured in 6-well dishes until 80% confluency. Cells were lysed
with 300 μl 2× Laemmli Buffer (Sigma Aldrich) and denatured for
5 min at 100˚C before being cooled on ice.
Western immunoblotting. Samples were separated on an SDS-10%
polyacrylamide gel and the proteins were transferred to a
nitrocellulose membrane. The membrane was blocked in TBS
containing 0.1% Tween-20 and 5% dried milk powder (wt/vol), for
1 h at room temperature. After a brief wash with PBS-0.1% Tween-
20, the nitrocellulose membranes were incubated with primary
antibodies against phospho-mTOR (Ser2448), total mTOR,
phospho-p70S6K (serine371/threonine389), and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Cell Signalling, USA; Sigma
Aldrich). The primary antisera were used at a 1:1000 dilution in
PBS-0.1% Tween-20 overnight at 4˚C. The membranes were washed
for 30 min with PBS-0.1% Tween-20, before incubation with the
secondary anti-rabbit horseradish peroxidase-conjugated
immunoglobulin (1:2000) for 1 h at room temperature and further
washing for 30 min with PBS-0.1% Tween-20. Antibody complexes
were visualised as previously described (26).
Statistical analysis. For the quantitative PCR, the following
equations were used: ΔCt=Ct(gene of interest)-Ct(house keeping gene),
ΔΔCt=ΔCt(sample)– ΔCt(calibrator), relative quantity (RQ)=2–ΔΔCt.
RQ value was set at 1 for the parental SKOV-3 and PEO1 cells
when compared to paclitaxel-resistant (TaxR) ones. Data are
reported as the mean±SD of three or four measurements. Statistical
analysis was performed by Student’s t-test and by ANOVA. P<0.05
was regarded as significant. 
Results
Rapamycin sensitivity of PEO1 parental and paclitaxel-
resistant PEO1TaxR cells. The half maximal inhibitory
concentration (IC50) value for rapamycin in PEO1 was
25.3±3.9 μM and for PEO1TaxR was 22.8±3.4 μM, p-
value=0.175 (n=4). The IC50 value for the combination of
rapamycin with XR9576 was unchanged for both cell lines,
at 25.1 and 22.4 μM for PEO1 and PEO1TaxR (n=2),
respectively.
Expression of DEPTOR, RICTOR, RAPTOR, and mTOR.
Quantitative RT-PCR revealed that DEPTOR, RICTOR,
RAPTOR, and mTOR are differentially expressed in
paclitaxel-sensitive and -resistant (TaxR) ovarian cancer
cell lines (n=3). There was an up-regulation of DEPTOR
(2.4-fold), RICTOR (1.5-fold) and mTOR (1.2-fold) in
PEO1TaxR ovarian cancer cells when compared with
paclitaxel-sensitive PEO1 cells. A down-regulation (0.6-
fold) was detected for RAPTOR (Figure 1A). With regards
to SKOV-3, a significant up-regulation of DEPTOR (1.8-
fold) and down-regulation of RAPTOR (0.6-fold),
RICTOR (0.7-fold) and mTOR (0.6-fold) was found in
SKOV-3TaxR cells when compared with parental SKOV-3
cells (Figure 2A). 
Protein expression and cellular distribution of mTOR. The
protein expression of mTOR was also assessed in these cell
lines, using immunofluorescent analysis. A similar intensity
in cytoplasmic staining was detected in both parental and
PEO1TaxR cells. In SKOV-3 cells, the staining was more
granular when compared with SKOV-3TaxR cells (Figure
1B). In PEO1 cells, no apparent differences in the intensity
or localization of mTOR were observed for either parental
or paclitaxel-resistant cells (Figure 2B).
Expression p70S6K isoforms in paclitaxel-sensitive and TaxR
cell lines. Semi-quantitative RT-PCR analysis corrected with
β-actin revealed that the expression of S6K α2 and β2
remained unaltered in SKOV-3 and PEO1 parental and
paclitaxel-resistant ovarian carcinoma cell lines alike (Figure
3). Interestingly, gene expression of S6Kα1 and β1 altered.
An up-regulation in the expression of S6Kα1 splice variant
in PEO1TaxR cells at the mRNA level was noted when
compared with control (paclitaxel-sensitive) PEO1 cells,
whereas S6Kβ1 was almost non-detectable in PEO1TaxR
cells. However, no apparent difference in the expression of
these two variants was detected between parental SKOV-3
and SKOV-3TaxR cells (Figure 3A).
Phosphorylation of mTOR and p70S6K in parental and TaxR
cell lines. The activity of mTOR and p70S6K was assessed
by measuring the phosphorylation status of these two
components. Under basal conditions (i.e. no treatments),
there was no apparent difference in the phosphorylation of
mTOR in Ser2448 in any of samples tested. Interestingly, a
notable down-regulation in the phosphorylation of Ser371
and Thr389 p70S6K was noted in both SKOV-3 and SKOV-
3TaxR compared with PEO1 parental and PEO1TaxR cells
(Figure 3B). 
Discussion
This study used two cell lines that have been developed to
study ovarian cancer drug resistance and signalling in vitro
(27). In particular, SKOV-3 cells have been used extensively
to dissect signalling pathways involved in the development
of epithelial ovarian cancer. The sensitivity of PEO1 and
PEO1TaxR cells to the cytotoxic effects of rapamycin were
determined, but no differences were ascertained.
Nevertheless, the effectiveness of rapamycin in MDR cell
lines has been implicated in this study. This manuscript
presents novel data on DEPTOR, a newly described
modulator of mTOR signalling as highlighted by an altered
expression in drug-resistant cells. The expression of
DEPTOR was up-regulated in both PEO1TaxR and SKOV-
3TaxR cells when compared with parental paclitaxel lines. A
recent study shows low expression of DEPTOR in most
types of cancer; however, it is highly overexpressed in a
Foster et al: mTOR Signalling in Drug Resistance
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Figure 1. A: Quantitative RT-PCR analysis of DEPTOR, RAPTOR and RICTOR and mTOR in PEO1 Parental and PEO1TaxR cells. B: Indirect
immunofluorescent analysis for mTOR in PEO1 (PEO1 parental and PEO1TaxR) cells showing the cytoplasmic distribution of mTOR (white arrows).
No apparent difference in mTOR protein expression between the two cell lines was noted. Negative serum controls confirmed specificity. The cell
nuclei were visualised with the DNA-specific dye DAPI.
Figure 2. A: Quantitative RT-PCR analysis revealed up-regulation of DEPTOR and down-regulation of mTOR, rector and RAPTOR in SKOV-3
parental cells when compared with paclitaxel-resistant cells. B: Immunofluorescent analysis for mTOR in SKOV-3 (SKOV-3 parental and SKOV-
3TaxR) cells revealed cytoplasmic distribution of mTOR. 
subset of multiple myelomas with cyclin D1/D3 or c-
MAF/MAFB translocations (23). The authors concluded that
the increased presence of DEPTOR in these cells drives the
activation of PI3K/Akt signalling cascade, promoting cell
survival. It is possible that in a state of drug resistance,
amplification of DEPTOR may lead to an increase in cell
proliferation and promote cancer progression through
increased survival. 
These data also suggest that expression of mTOR
signalling components may be cell type specific. For
instance, RICTOR and mTOR expression were up-regulated
in the PEO1TaxR cells, whereas their expression was
markedly down-regulated in SKOV-3TaxR ovarian cancer
cells. These data imply a higher order of complexity in the
cross-talk between mTOR and its interacting protein
DEPTOR. This differential expression of mTOR signalling
components in these cell lines could be due to distinct
characteristics of each cell line. For example, SKOV-3 cells
do not express p53 and inhibition of mTOR activity with
rapamycin resulted in G1 arrest in SKOV-3 cells but not in
OVCAR4 or OVCAR5 cells (16). These distinct
characteristics suggest that each ovarian cancer cell line
might differ with regards to their ability to respond to drug
resistance. Consequently, downstream signalling cascades
including mTOR could also be differentially regulated.
Cellular localization of mTOR may have important
implications for expression and consequently cancer
treatment. mTOR protein is localised within the cytoplasm
in both ovarian cancer cell lines. These data are in agreement
with previous studies demonstrating the cytoplasmic
localization of mTOR (28). Another study argued that mTOR
can also shuttle between the nucleus and cytoplasm, an event
necessary for the maximal activation of S6K1 (29); however,
we did not detect nuclear localisation of mTOR in the cell
lines used in this study. Interestingly, cytoplasmic mTOR
protein expression was lower in the TaxR SKOV-3 cells
when compared with paclitaxel-sensitive cells, in agreement
with the quantitative RT-PCR analysis. Future studies could
determine the cellular localisation of mTOR in ovarian
tumours before and during drug treatment. Moreover, it will
be interesting to map the cellular distribution of DEPTOR in
ovarian tumours upon availability of a commercially
available antibody. The activity of mTOR and p70S6K was
assessed by measuring changes in the phosphorylation of
these key kinases. Our data indicate that phosphorylation of
these enzymes is differentially regulated in the ovarian
cancer cell lines, suggesting further cell type-specific effects.
This is particularly evident in SKOV-3 cells, where an
association is evident between the dephosphorylation of
p70S6K at Ser371 and Thr389. This concurs with studies
showing that Ser371 phosphorylation regulates the
phosphorylation status of Thr389 and directly influences
S6K activity (30). 
Collectively these novel data provide evidence that human
ovarian cancer cell lines express mTOR and its downstream
signalling components. Indeed paclitaxel resistance can
affect gene expression and activity of these components,
emphasising the significance of this pathway in both tumour
development and treatment. The implications of the mTOR
signalling pathway in the development of paclitaxel
resistance in ovarian cancer may be paramount in
determining future strategies to overcome this.
Foster et al: mTOR Signalling in Drug Resistance
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Figure 3. A: Semi-quantitative RT-PCR analysis of mTOR and p70S6K
variants. Lane 1: DNA marker, lane 2: cDNA from SKOV-3 parental
cells, lane 3: cDNA from PEO1 parental cells, lane 4: cDNA from
SKOV-3TaxR cells, and lane 5: cDNA from PEO1TaxR cells. B: Western
blot depicting changes in the phosphorylation status of p70S6K and
mTOR under basal conditions in paclitaxel parental and TaxR ovarian
carcinoma cell lines, when compared with GAPDH. Lane 1: lysates
from PEO1 parental cells, lane 2: lysates from PEO1TaxR cells, lane
3: lysates from SKOV-3 parental cells, and lane 4: lysates from SKOV-
3TaxR cells. 
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